|
|||||
|
|
||||||
Erratum
for
Stewart et al., © 2009 American Society of Clinical Oncology. DOI: 10.1200/JCO.2009.24.4558 ERRATAThe April 10, 2009, article by Stewart et al, entitled, "Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck" (J Clin Oncol 27:1864–1871, 2009), contained errors.The Title should have read: "Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck." In the Patients and Methods section, under Overall Study Design, CTC was defined in the last sentence as Common Toxicity Criteria, whereas it should have been Common Terminology Criteria. In Table 3, CTC was also defined as Common Toxicity Criteria and should have been Common Terminology Criteria. In Figure 1, the following footnote was inadvertently omitted: "Evaluable for efficacy, all randomized patients; Evaluable for response, patients with unidimensional measurable disease at baseline as per the Response Evaluation Criteria In Solid Tumors (RECIST) criteria; Evaluable for safety, all patients who received at least 1 dose of study treatment; Evaluable for quality of life, patients with an evaluable baseline quality of life assessment and at least 1 evaluable post-baseline quality of life assessment." In the legend of Figure 4, parts A and B were mislabeled and should have been: (A) EGFR FISH-positive; (B) EGFR FISH-negative. In the Contributions section, Ezra E.W. Cohen should have been acknowledged for collection and assembly of data. The online only Appendix was inadvertently omitted. The online version has been corrected in departure from the print.
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|